Advancements in the clinical applications of small interfering RNA (siRNA) in cancer therapy
have opened up new possibilities for precision medicine. siRNAs, as powerful genetic tools …

Background: Cisplatin, a platinum complex discovered by Rosenberg in 1969, has long
been known as the first metal-based anticancer agent. Since then, various similar …

Objective: Cancer poses a significant challenge in modern medicine, standing as the
primary cause of death in many countries, second only to cardiovascular diseases. Among …

This study aimed to develop and evaluate phosphatidylserine (PS)-targeted nanoparticles
for efficient delivery of methotrexate to tumor sites. Therefore, methotrexate-loaded …

Objective Nisin is an antibacterial peptide with anticancer properties, but the main drawback
is its rapid enzymatic degradation and limited permeation across the cell membrane. This …

Glioblastoma (GBM) is an aggressive and lethal malignancy of the central nervous system
with a median survival rate of 15 months. We investigated the combined anticancer effects of …

Objective: Breast cancer is one of the most prevalent malignancies and leading causes of
females' mortality worldwide. Because of resistance to various treatment options, new …

Objective: Today, cancer is one the most important challenges in modern medicine.
Meanwhile, breast cancer is one of the most common causes of mortality among cancers …

Purpose: Dihydropyrimidine dehydrogenase (DPD) is the principal enzyme in the
catabolism of fluoropyrimidine drugs including capecitabine. A recent report has suggested …

The aim of this review was to explore the advances of nanoformulations as a strategy to
optimize glioblastoma treatment, specifically focusing on targeting and controlling drug …